|Dr. Alexander D. Macrae||CEO, Pres & Director||1.06M||N/A||1963|
|Mr. Stéphane Boissel||Interim CFO & Exec. VP of Corp. Strategy||537.27k||N/A||1968|
|Ms. Prathyusha Durabaibu||Principal Accounting Officer||N/A||N/A||1979|
|Dr. Edward Rebar||Sr. VP & CTO||N/A||N/A||N/A|
|Mr. McDavid Stilwell||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Sangamo Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 2; Compensation: 5.